A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

Mease, Pj; Smolen, Js; Behrens, F; Nash, P; Leage, Sl; Li, Ln; Tahir, H; Gooderham, M; Krishnan, E; Liu-Seifert, H; Emery, P; Pillai, Sg; Helliwell, Ps; Naftal, L; Hidalgo, Rap; Kerzberg, Em; Savio, Vg; Lazaro, A; Velasco, Bj; Verzero, Nb; Asnal, Ca; Mysler, Ef; Berman, A; Ariel, Fj; Rischmueller, M; Zochling, Jm; Bird, Pa; Hall, S; Ostor, A; Romas, E; Stummvoll, G; Machold, K; Spellitz, P; Hanusch, U; Vanden Berghe, M; Leon, M; Vanhoof, Jlm; Van den Bosch, Fej; De Vlam, Klf; Morin, F; Bessette, L; Haaland, Da; Schlemmer, Am; Kristensen, Le; Jarvinen, P; Peltomaa, Rl; Pirila, L; Vuotila, J; Lespessailles, E; Goupille, P; Combe, B; Constantin, A; Cormier, G; Cozic, C; Confavreux, Cb; Schulze-Koops, H; Everding, A; Kohm, M; Wassenberg, S; Nagy, M; Bakos, N; Melegh, E; Drescher, E; Duggal, L; Joshi, Pn; Zoha, Sg; Naidu, Ar; Srivastava, Pp; Sharma, Vd; Nalawadae, Ab; Oak, Jl; Veeravalli, Scm; Kadel, Jk; Daware, Ma; Marfatia, Ys; Agarwal, S; Moscovici, Yb; Elkayam, O; Molad, Y; Reitblat, T; Tishler, M; Levy, Y; Lidar, M; Zisman, D; Costanzo, A; Amerio, P; Meliconi, R; Foti, R; Perricone, R; Rossini, M; Gremese, E; Montiel, Bez; Limon, Jmm; Cecena, Mam; Ayala, Sas; Guerrero, Maa; Serrano, Jr; Novelo, Eac; Cons-Molina, Ff; Griep, En; Kaszuba, A; Weglowska, Jb; Bazela, B; Rell-Bakalarska, M; Miakisz, M; Spargo, Ce; Van Duuren, Em; Naidoo, A; Matsiliza, Nc; Breedt, J; Tarr, Gs; Potts, J; Nayiager, S; Ally, Mmtm; Garcia, Fjb; Varela, Am; Rosas, J; Burson, Jms; Miguel, Jg; Lampa, J; Rizk, M; Cagnotto, G; Larsson, P; Fei, G; Mueller-Mar, R; Rubbert-Roth, A; Nissen, Mj; Iaremenko, O; Trypilka, Sa; Rekalov, D; Stanislavchuk, M; Vasylets, Vv; Garmish, O; Smiyan, S; Walker, D; Jadon, D; Ralston, S; Boyle, S; Watson, Pa; Dale, Je; Carty, S; Douglas, K; Edwards, Cj; Hutchinson, D; Barkham, N